RhumbLine Advisers
SGMT icon

RhumbLine Advisers’s Sagimet Biosciences SGMT Stock Holding History

RhumbLine Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$575K Buy
+74,339
New +$506K ﹤0.01% 2678
2024
Q3 		– Sell
-6,111
Closed -$20.9K – 4316
2024
Q2 		$20.9K Sell
6,111
-6,706
-52% -$30.8K ﹤0.01% 3865
2024
Q1 		$69.5K Buy
12,817
+7,513
+142% +$54K ﹤0.01% 3549
2023
Q4 		$28.7K Sell
5,304
-186
-3% -$877 ﹤0.01% 3722
2023
Q3 		$48.3K Buy
+5,490
New +$73.1K ﹤0.01% 3648

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RhumbLine Advisers's SGMT Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 74,339 shares worth $575K. The stake represents ﹤0.01% of the portfolio and ranks #2678 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in SGMT as recently as Q2 2024.

RhumbLine Advisers first reported a position in SGMT in Q3 2023 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • RhumbLine Advisers held 74,339 shares of Sagimet Biosciences worth $575K as of Q2 2026.
  • Sagimet Biosciences was a new RhumbLine Advisers position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2678 holding.
  • RhumbLine Advisers first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.